Component

Gut microbiota, hepatic/renal markers and appetite-hormone panel in prediabetes

Species, preparation, dose and limitations are retained on linked claims.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. The same 12-week trial found no between-group differences in gut microbiota composition, hepatic or renal function markers, or the measured appetite-controlling hormones.

    Experimental context and source evidence
    dose
    2.4 g/day dry leaf powder or placebo
    duration
    12 weeks
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    evidence_scope
    literature_reviewed; model-specific source-derived curation
    experimental_model
    Adults with prediabetes
    limitations
    The null applies to the measured endpoints, sample and exposure; it does not establish that every product is inert.
    nutrient_topic
    Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
    organism
    Adults with prediabetes
    plain_language
    The same 12-week trial found no between-group differences in gut microbiota composition, hepatic or renal function markers, or the measured appetite-controlling hormones.
    primary_references
    Moringa oleifera Leaf Supplementation as a Glycemic Control Strategy in Subjects with Prediabetes. (2021). https://pubmed.ncbi.nlm.nih.gov/35010932/ DOI: 10.3390/nu14010057
    route
    Oral
    tissue
    Microbiota, organ-function markers and appetite hormones

    Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 145–154

    Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Adults with prediabetes · source_derived_draft · unverified_draft

    ## moringa-prediabetes-metabolic-null The same 12-week trial found no between-group differences in gut microbiota composition, hepatic or renal function markers, or the measured appetite-controlling hormones. Model/species: Adults with prediabetes Tissue/system: Microbiota, organ-function markers and appetite hormones Exposure: 2.4 g/day dry leaf powder or placebo Route: Oral Duration: 12 weeks Limits: The null applies to the measured endpoints, sample and exposure; it does not establish that every product is inert. Primary reference: Moringa oleifera Leaf Supplementation as a Glycemic Control Strategy in Subjects with Prediabetes. (2021). https://pubmed.ncbi.nlm.nih.gov/35010932/ DOI: 10.3390/nu14010057 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards